Cyclophosphamide (CPA), an alkylating prodrug, has been used extensively in the treatment of hematologic malignancies, in particular, as an important component in the front-line regimens for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Unfortunately, despite aggressive chemotherapy, a significant number of patients remain uncured due to development of drug resistance and/or intolerable toxicities. The need for further optimization of the current regimens is evident. The overall goal of this proposal is to improve the therapeutic efficacy of CPA-based chemotherapy by enhancing metabolic conversion of CPA to the pharmacologically active 4-hydroxylcyclophosphamide (4-OH-CPA) via CYP2B6, but not to the N- dechloroethyl-cyclophosphamide and the toxic chloroacetaldehyde by CYP3A4. Towards this end, we have shown that activation of the human constitutive androstane receptor (hCAR) preferentially induced the expression of hepatic CYP2B6 over CYP3A4 and increased the formation of 4-OH-CPA. We have also developed a unique human primary hepatocyte (HPH)-leukemia coculture model and demonstrated that co- administration of CPA with a selective hCAR activator leads to significantly enhanced apoptosis in leukemia cells without increasing hepatotoxicity. In this application, we hypothesize that activation of hCAR can selectively enhance systemic exposure to 4-OH-CPA and increase the efficacy:toxicity ratio of CPA-based treatment for lymphoma and leukemia. This central hypothesis will be tested by the following specific aims:
Aim #1. Evaluate the role of hCAR in the bioactivation of CPA in HPH and lymphoma/leukemia cells;
Aim #2. Assess the metabolism and anticancer activity of CPA in the HPH-lymphoma/leukemia coculture model;
and Aim #3. Examine the influence of hCAR activation on CPA-based treatment of lymphoma/leukemia in an hCAR-transgenic mouse model. The outcomes are expected to establish hCAR as a novel therapeutic target facilitating the CPA-based chemotherapy for hematopoietic malignancies. Improved understanding of the underlying mechanism(s) associated with hCAR-mediated enhancement of the anticancer activity of CPA may ultimately benefit the development of new therapeutic strategies.

Public Health Relevance

We will evaluate the role of hCAR in the metabolism and anticancer activity of CPA using our newly developed human hepatocyte-leukemia coculture model in vitro and a hCAR-transgenic mouse model in vivo. We expect that results from the proposed research will fundamentally advance our understanding of the molecular modulation of CPA bioactivation, and will eventually benefit the development of novel therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM107058-01
Application #
8556721
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Okita, Richard T
Project Start
2013-09-01
Project End
2017-05-31
Budget Start
2013-09-01
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$291,650
Indirect Cost
$101,650
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72
Li, Linhao; Li, Daochuan; Heyward, Scott et al. (2016) Transcriptional Regulation of CYP2B6 Expression by Hepatocyte Nuclear Factor 3β in Human Liver Cells. PLoS One 11:e0150587
Mackowiak, Bryan; Wang, Hongbing (2016) Mechanisms of xenobiotic receptor activation: Direct vs. indirect. Biochim Biophys Acta 1859:1130-40
Hedrich, William D; Hassan, Hazem E; Wang, Hongbing (2016) Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 6:413-425
Hedrich, William D; Xiao, Jingwei; Heyward, Scott et al. (2016) Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. Mol Cancer Ther 15:392-401
Lynch, Caitlin; Zhao, Jinghua; Huang, Ruili et al. (2015) Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor. Sci Rep 5:10405
Li, Daochuan; Mackowiak, Bryan; Brayman, Timothy G et al. (2015) Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells. Biochem Pharmacol 98:190-202
Wang, An-Jiang; Yang, Zhonghan; Grinchuk, Viktoriya et al. (2015) IL-25 or IL-17E Protects against High-Fat Diet-Induced Hepatic Steatosis in Mice Dependent upon IL-13 Activation of STAT6. J Immunol 195:4771-80
Li, Linhao; Li, Haishan; Garzel, Brandy et al. (2015) SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver. Mol Pharmacol 87:674-82
Yang, Hui; Garzel, Brandy; Heyward, Scott et al. (2014) Metformin represses drug-induced expression of CYP2B6 by modulating the constitutive androstane receptor signaling. Mol Pharmacol 85:249-60

Showing the most recent 10 out of 15 publications